Ionis Pharmaceuticals in 2015
Ionis Pharmaceuticals (IONS) is a biopharmaceutical company focused on the discovery and development of RNA-targeted therapeutics. The company has created a broadly applicable drug discovery platform. Through it, the company has developed a diverse pipeline for potentially best-in-class drugs for patients with significant unmet medical needs. The company’s revenues increased more than 32% to $284 million in 2015, compared to $214 million in 2014.
The above graph shows the company’s revenue trend over the last few years. Ionis has reported an increase in research and development revenues, partially offset by the decrease in licensing and royalty revenues. We’ll look at these in more detail in the rest of this series.
Ionis has discovered and is developing the following three drugs:
- nusinersen for the treatment of patients with spinal muscular atrophy, a leading cause of infant mortality
- Ionis-TTRRx for the treatment of patients with transthyretin amyloidosis, a fatal disease in which amyloid plaque deposits in tissues increase progressively throughout the body
- volanesorsen for the treatment of patients with an extremely high level of triglycerides
These drugs are designed to treat diseases with limited or no therapeutic options. The company has collaborative agreements with Biogen Idec (BIIB) for nusinersen and GlaxoSmithKline (GSK) for IONIS-TTRRx.
Analyst estimates show Ionis Pharmaceuticals’ 2016 revenue at $237 million. That’s a decline of more than 16% compared to $284 million for 2015. Analysts are estimating revenues to increase to $278 million in 2017.
To avoid the risk of investing in one stock, you can consider the iShares Nasdaq Biotech (IBB), which holds ~1.0% of its total assets in Ionis. You can also consider the SPDR S&P Biotech ETF (XBI), which holds ~1.2% of its total assets in Ionis. XBI also holds 2.7% of its total assets in Acadia Pharmaceuticals (ACAD), 2.3% in Medivation (MDVN), 2.1% in Novavax (NVAX), and 2.0% in Ligand Pharmaceuticals (LGND).
In the next part of our series, we’ll explore Ionis Pharmaceuticals’ 2015 revenue stream.